# A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

> **NCT00517530** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 134 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT00517530
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517530, "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00517530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*